- Home
- / Achilles Therapeutics
Achilles Therapeutics
Total Funding
$138.1 M
Achilles Therapeutics Summary
Company Summary
- Overview
- Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. Its immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
- Type
- Private
- Status
- Active
- Founded
- 2016
- HQ
- London, GB | view all locations
- Website
- https://achillestx.com/
- Cybersecurity rating
Table of Contents
Key People
Karl Peggs, Chief Medical Officer
Sergio Quezada, Chief Scientific Officer
Robert Coutts, Chief Financial Officer
Operating MetricsView all
Manufacturing Space, sq. ft.
64.2K
FY, 2020
Office and Laboratory Space, square feet
24.6K
FY, 2020
Trademarks (US)
3
May, 2021
LocationsView all
2 locations detected
London, England HQ
United Kingdom
Bechtel House, 245 Hammersmith Rd, Hammersmith
Stevenage, England
United Kingdom
Gunnels Wood Rd
Achilles Therapeutics Financials
Summary Financials
- Net income (FY, 2022)
- ($71.2M)
- Cash (FY, 2022)
- $173.3M
- EBIT (FY, 2022)
- ($78.4M)